Pagán José A, Carlson Erin K
University of North Texas Health Science Center, Fort Worth, TX, USA.
J Prim Care Community Health. 2013 Oct;4(4):281-5. doi: 10.1177/2150131913489885. Epub 2013 May 24.
The patient-centered medical home (PCMH) is an integrated primary care delivery model particularly suited for patients with poor diabetes control. Although PCMH models targeting adults with diabetes have shown some early success, little is known about the long-term benefits of medical homes in terms of health and cost outcomes. The performance of a PCMH model in adults with poor diabetes control was assessed using simulated controlled trial data obtained from the Archimedes model of disease progression and health care utilization. Using the Cardio-Metabolic Risk data set, we compared health and cost outcomes over a 20-year period between adults with poor diabetes control (HbA1c >9%) receiving standard care and these same adults receiving care under a PCMH model with a 49% HbA1c intervention improvement rate at a per-beneficiary per-month care management cost of $20 per month. The results suggest that the PCMH model has the potential to not only reduce the proportion of the population with bilateral blindness, foot amputations, and myocardial infarctions-and the mortality rate-but it can also do so in a cost-effective manner ($7898 per quality-adjusted life year). The PCMH model is cost saving for the population 50 to 64 years old and it is particularly cost-effective for men ($883 per quality-adjusted life year). Moreover, these effects are relatively large for adults 30 to 49 years old (lower bilateral blindness and death rates), women (lower foot amputation and death rates), and men (lower bilateral blindness and myocardial infarction rates). The PCMH model has potential long-term benefits to both patients with poor diabetes control as well as health care systems and providers willing to invest in this health care delivery approach.
以患者为中心的医疗之家(PCMH)是一种综合初级保健服务模式,特别适合糖尿病控制不佳的患者。尽管针对成年糖尿病患者的PCMH模式已显示出一些早期成效,但对于医疗之家在健康和成本效益方面的长期益处却知之甚少。我们使用从阿基米德疾病进展和医疗保健利用模型获得的模拟对照试验数据,评估了PCMH模式在糖尿病控制不佳的成年人中的效果。利用心血管代谢风险数据集,我们比较了糖尿病控制不佳(糖化血红蛋白>9%)的成年人接受标准护理与接受PCMH模式护理(糖化血红蛋白干预改善率为49%,每位受益人的每月护理管理成本为每月20美元)在20年期间的健康和成本效益。结果表明,PCMH模式不仅有可能降低双侧失明、足部截肢和心肌梗死人群的比例以及死亡率,而且还能以具有成本效益的方式做到这一点(每质量调整生命年7898美元)。PCMH模式对50至64岁人群具有成本节约效益,对男性尤其具有成本效益(每质量调整生命年883美元)。此外,对于30至49岁的成年人(降低双侧失明和死亡率)、女性(降低足部截肢和死亡率)以及男性(降低双侧失明和心肌梗死率),这些影响相对较大。PCMH模式对糖尿病控制不佳的患者以及愿意投资于这种医疗服务提供方式的医疗系统和提供者都具有潜在的长期益处。